Moreover, treatment of CAD patients with ACE inhibitor, lipid-lowering drug, and anti-inflammatory compound decreased MMP-2 activity and levels, indicating that the inhibition of MMP-2 is useful in treating CAD. The gene discussed is ACE; the disease is coronary artery disorder.